Skip to main content
Premium Trial:

Request an Annual Quote

Pfizer and Perlegen Ink SNP Collaboration on Metabolic Syndrome

NEW YORK, Jan. 7 (GenomeWeb News) - Perlegen Sciences and Pfizer have started a research collaboration to discover genetic markers for metabolic syndrome, Perlegen said today.


Perlegen, located in Mountain View, Calif., will use its genotyping technology to analyze thousands of patient samples for SNPs associated with metabolic syndrome. Pfizer will provide Perlegen with research funding and milestone payments and license the technology. The companies will share any therapeutic and diagnostic rights resulting from the collaboration.


Metabolic syndrome greatly increases the risk of developing cardiovascular disease and type 2 diabetes.


The Scan

Two J&J Doses

Johnson & Johnson says two doses of its SARS-CoV-2 vaccine provides increased protection against symptomatic COVID-19, CNN reports.

Pfizer-BioNTech Vaccine Response in Kids

The Pfizer-BioNTech SARS-CoV-2 vaccine in a lower-dose format appears to generate an immune response among children, according to the Washington Post.

Chicken Changes to Prevent Disease

The Guardian writes that researchers are looking at gene editing chickens to help prevent future pandemics.

PNAS Papers on Siberian Dog Ancestry, Insect Reproduction, Hippocampal Neurogenesis

In PNAS this week: ancestry and admixture among Siberian dogs, hormone role in fruit fly reproduction, and more.